The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection?

View More View Less
  • 1 Departments of Neurosurgery and
  • 3 Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas; and
  • 2 Department of Neurosurgery and Oncology, University of Rochester Medical Center School of Medicine and Dentistry, Rochester, New York
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00
Print or Print + Online

OBJECT

Glioblastoma multiforme (GBM) is the most common and deadliest primary brain tumor. The value of extent of resection (EOR) in improving survival in patients with GBM has been repeatedly confirmed, with more extensive resections providing added advantages. The authors reviewed the survival of patients with significant EORs and assessed the relative benefit/risk of resecting 100% of the MRI region showing contrast-enhancement with or without additional resection of the surrounding FLAIR abnormality region, and they assessed the relative benefit/risk of performing this additional resection.

METHODS

The study cohort included 1229 patients with histologically verified GBM in whom ≥ 78% resection was achieved at The University of Texas MD Anderson Cancer Center between June 1993 and December 2012. Patients with > 1 tumor and those 80 years old or older were excluded. The survival of patients having 100% removal of the contrast-enhancing tumor, with or without additional resection of the surrounding FLAIR abnormality region, was compared with that of patients undergoing 78% to < 100% EOR of the enhancing mass. Within the first subgroup, the survival durations of patients with and without resection of the surrounding FLAIR abnormality were subsequently compared. The data on patients and their tumor characteristics were collected prospectively. The incidence of 30-day postoperative complications (overall and neurological) was noted.

RESULTS

Complete resection of the T1 contrast-enhancing tumor volume was achieved in 876 patients (71%). The median survival time for these patients (15.2 months) was significantly longer than that for patients undergoing less than complete resection (9.8 months; p < 0.001). This survival advantage was achieved without an increase in the risk of overall or neurological postoperative deficits and after correcting for established prognostic factors including age, Karnofsky Performance Scale score, preoperative contrast-enhancing tumor volume, presence of cyst, and prior treatment status (HR 1.53, 95% CI 1.33–1.77, p < 0.001). The effect remained essentially unchanged when data from previously treated and previously untreated groups of patients were analyzed separately. Additional analyses showed that the resection of ≥ 53.21% of the surrounding FLAIR abnormality beyond the 100% contrast-enhancing resection was associated with a significant prolongation of survival compared with that following less extensive resections (median survival times 20.7 and 15.5 months, respectively; p < 0.001). In the multivariate analysis, the previously treated group with < 53.21% resection had significantly shorter survival than the 3 other groups (that is, previously treated patients who underwent FLAIR resection ≥ 53.21%, previously untreated patients who underwent FLAIR resection < 53.21%, and previously untreated patients who underwent FLAIR resection ≥ 53.21%); the previously untreated group with ≥ 53.21% resection had the longest survival.

CONCLUSIONS

What is believed to be the largest single-center series of GBM patients with extensive tumor resections, this study supports the established association between EOR and survival and presents additional data that pushing the boundary of a conventional 100% resection by the additional removal of a significant portion of the FLAIR abnormality region, when safely feasible, may result in the prolongation of survival without significant increases in overall or neurological postoperative morbidity. Additional supportive evidence is warranted.

ABBREVIATIONSEOR = extent of resection; GBM = glioblastoma multiforme; KPS = Karnofsky Performance Scale; MD Anderson = The University of Texas MD Anderson Cancer Center; UCSF = University of California, San Francisco.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $505.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $600.00

Contributor Notes

Correspondence Raymond Sawaya, Department of Neurosurgery, Unit 442, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030. email: rsawaya@mdanderson.org.

* Drs. Li and Suki contributed equally to this work.

INCLUDE WHEN CITING Published online October 23, 2015; DOI: 10.3171/2015.5.JNS142087.

Disclosure This work was supported by a generous gift from the Apache Corporation.

  • 1

    Altman DG, , Lausen B, , Sauerbrei W, & Schumacher M: Dangers of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829835, 1994

    • Search Google Scholar
    • Export Citation
  • 2

    Bernstein JJ, , Goldberg WJ, , Laws ER Jr, , Conger D, , Morreale V, & Wood LR: C6 glioma cell invasion and migration of rat brain after neural homografting: ultrastructure. Neurosurgery 26:622628, 1990

    • Search Google Scholar
    • Export Citation
  • 3

    Burger PC, , Dubois PJ, , Schold SC Jr, , Smith KR Jr, , Odom GL, & Crafts DC, : Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159169, 1983

    • Search Google Scholar
    • Export Citation
  • 4

    Burger PC, , Heinz ER, , Shibata T, & Kleihues P: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68:698704, 1988

    • Search Google Scholar
    • Export Citation
  • 5

    Cerame MA, , Guthikonda M, & Kohli CM: Extraneural metastases in gliosarcoma: a case report and review of the literature. Neurosurgery 17:413418, 1985

    • Search Google Scholar
    • Export Citation
  • 6

    Choucair AK, , Levin VA, , Gutin PH, , Davis RL, , Silver P, & Edwards MS, : Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65:654658, 1986

    • Search Google Scholar
    • Export Citation
  • 7

    Dolecek TA, , Propp JM, , Stroup NE, & Kruchko C: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol 14:Suppl 5 v1v49, 2012

    • Search Google Scholar
    • Export Citation
  • 8

    Earnest FIV, , Kelly PJ, , Scheithauer BW, , Kall BA, , Cascino TL, & Ehman RL, : Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166:823827, 1988

    • Search Google Scholar
    • Export Citation
  • 9

    Ebos JM, , Lee CR, & Kerbel RS: Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res 15:50205025, 2009

    • Search Google Scholar
    • Export Citation
  • 10

    Greene GM, , Hitchon PW, , Schelper RL, , Yuh W, & Dyste GN: Diagnostic yield in CT-guided stereotactic biopsy of gliomas. J Neurosurg 71:494497, 1989

    • Search Google Scholar
    • Export Citation
  • 11

    Hochberg FH, & Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907911, 1980

  • 12

    Ibayashi N, , Herman MM, , Boyd JC, & Rubinstein LJ: Relationship of invasiveness to proliferating activity and to cyto-skeletal protein production in human neuroepithelial tumors maintained in an organ culture system: use of human cortex and dura as supporting matrices. Neurosurgery 26:629637, 1990

    • Search Google Scholar
    • Export Citation
  • 13

    Kelly PJ, , Daumas-Duport C, , Kispert DB, , Kall BA, , Scheithauer BW, & Illig JJ: Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66:865874, 1987

    • Search Google Scholar
    • Export Citation
  • 14

    Kreisl TN: Chemotherapy for malignant gliomas. Semin Radiat Oncol 19:150154, 2009

  • 15

    Lacroix M, , Abi-Said D, , Fourney DR, , Gokaslan ZL, , Shi W, & DeMonte F, : A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190198, 2001

    • Search Google Scholar
    • Export Citation
  • 16

    Lang FF, , Sawaya R, , Suki D, , McCutcheon IE, & Hess KR: Glioblastoma resection. J Neurosurg 116:11661167, author reply 1167–1168, 2012

  • 17

    Leifer D, , Moore T, , Ukena T, , Wilner D, , Thor A, & Hedley-Whyte ET: Multifocal glioblastoma with liver metastases in the absence of surgery. Case report. J Neurosurg 71:772776, 1989

    • Search Google Scholar
    • Export Citation
  • 18

    Liwnicz BH, & Rubinstein LJ: The pathways of extraneural spread in metastasizing gliomas: a report of three cases and critical review of the literature. Hum Pathol 10:453467, 1979

    • Search Google Scholar
    • Export Citation
  • 19

    Marko NF, , Weil RJ, , Schroeder JL, , Lang FF, , Suki D, & Sawaya RE: Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol 32:774782, 2014

    • Search Google Scholar
    • Export Citation
  • 20

    Sanai N, , Polley MY, , McDermott MW, , Parsa AT, & Berger MS: An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 115:38, 2011

    • Search Google Scholar
    • Export Citation
  • 21

    Sawaya R, , Hammoud M, , Schoppa D, , Hess KR, , Wu SZ, & Shi WM, : Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42:10441056, 1998

    • Search Google Scholar
    • Export Citation
  • 22

    Stummer W, , Tonn JC, , Mehdorn HM, , Nestler U, , Franz K, & Goetz C, : Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg 114:613623, 2011

    • Search Google Scholar
    • Export Citation
  • 23

    Van Meir EG, , Hadjipanayis CG, , Norden AD, , Shu HK, , Wen PY, & Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60:166193, 2010

    • Search Google Scholar
    • Export Citation
  • 24

    Vertosick FT Jr, & Selker RG: Brain stem and spinal metastases of supratentorial glioblastoma multiforme: a clinical series. Neurosurgery 27:516522, 1990

    • Search Google Scholar
    • Export Citation
  • 25

    Wallner KE, , Galicich JH, , Krol G, , Arbit E, & Malkin MG: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:14051409, 1989

    • Search Google Scholar
    • Export Citation
  • 26

    Wilson CB: Glioblastoma: the past, the present, and the future. Clin Neurosurg 38:3248, 1992

  • 27

    Yung WA, , Horten BC, & Shapiro WR: Meningeal gliomatosis: a review of 12 cases. Ann Neurol 8:605608, 1980

  • 28

    Zinn PO, , Mahajan B, , Sathyan P, , Singh SK, , Majumder S, & Jolesz FA, : Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiforme. PLoS One 6:e25451, 2011. Erratum in PLoS One 7:10.1371/annotation/b5267cb3-6aa7-47fc-a648-47f30a7cff3e, 2013

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2823 1170 101
PDF Downloads 1167 501 57
EPUB Downloads 0 0 0